Kenneth Vega, MD
Gastroenterology · Augusta, GANPI 1962479238
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $50,200 of the $59,417 with a category attached, or 84.5%. Phathom Pharmaceuticals, Inc. accounts for 90.3% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2024 at $44,336 and has fallen 76.9% since, to $10,242 in 2025. Among gastroenterology clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 98 payments — averaging $606.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Phathom Pharmaceuticals, Inc.$54K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$3K
- GI Supply, Inc.$425
- Regeneron$420
- Steris Corporation$398
- Covidien LP$358
- plus $1K from 12 others
Across 6 payments — averaging $9485.17 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bausch Health US, LLC$47K
- Cook Research Incorporated$10K
What the payments were for
- Speaking & faculty fees$50,20084%
- Travel & lodging$4,4007%
- Food & beverage$4,8178%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Phathom Pharmaceuticals, Inc. | 44 | $53,678 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 18 | $3,107 |
| GI Supply, Inc. | 2 | $425 |
| Regeneron | 5 | $420 |
| Steris Corporation | 3 | $398 |
| Covidien LP | 6 | $358 |
| Laborie Medical Technologies Corp. | 4 | $311 |
| Lucid Diagnostics Inc. | 3 | $297 |
| QOL Medical, LLC | 4 | $130 |
| Madrigal Pharmaceuticals | 1 | $121 |
| Braintree Laboratories, Inc. | 1 | $42 |
| AbbVie | 1 | $23 |
| Lilly USA, LLC | 1 | $22 |
| Medtronic | 1 | $21 |
| Bristol Myers Squibb | 1 | $18 |
| Ipsen Biopharmaceuticals, Inc | 1 | $18 |
| Sanofi | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$59,417 in reported general payments places this provider in the 95th percentile of 492 gastroenterology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 61 | $956 |
| Omeprazole | 39 | $651 |
| Esomeprazole Magnesium | 12 | $452 |
| Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl | 18 | $299 |
| Pantoprazole Sodium | 15 | $52 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Augusta
- Satish RaoAugusta$335K
- Bryan CurtinAugusta$82K
- Sunil LalAugusta$26K
- Nitin GuptaAtlanta$1.1M
- Cynthia RudertAtlanta$720K
- Douglas WolfAtlanta$668K
- Kavita KongaraAtlanta$492K
- Girish AnandAtlanta$425K
- Roshan ShresthaAtlanta$317K
- Hetal KarsanAtlanta$314K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.